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As the societal and economic burdens of Alzheimer’s disease (AD) continue to mount, so does the need for therapies that slow
the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has
seensigniﬁcantprogressinthedevelopment ofvariousimmunotherapeuticapproachestargetingbetaamyloid.Thispaperreviews
active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.
1.Introduction
Alzheimer’s disease (AD) is by far the most common form
of dementia, and the social and economic burdens of AD
continue to mount. In 2010, an estimated 36 million people
worldwide were living with dementia—a number that is
projectedtoincreaseto66millionin2030,and115millionin
2050 [1]. According to the World Alzheimer Report, the
worldwide cost of dementia is estimated at USD $604 billion
for 2010 [1], and according to one model, this cost has
increasedby34%between2005and2009[2].Thesestatistics
must be considered in parallel with the immeasurable
emotional and psychological burdens that AD places on
patients and families.
Signiﬁcant progress in the treatment of AD has been
made since the initial description of the disease by Alois
Alzheimer in 1907 [3]. Cholinesterase inhibitors and me-
mantine are potential therapies for the management of many
cognitivesymptomsofAD,buttheseneurotransmitter-based
approaches do not address the underlying pathology of
the illness, and ultimately fail to prevent its progression.
The pathologic triad of AD—the accumulation of toxic
beta amyloid with the formation of extracellular beta-
amyloid-containing plaques, the development of intracellu-
lar neuroﬁbrillary tangles, and the degeneration of cerebral
neurons—provides numerous potential targets for disease-
modifying therapies. Multiple lines of evidence now suggest,
however, that it is the production and/or deposition of toxic
forms of beta amyloid, along with the slowing of beta-
amyloid clearance, that act as the central and primary events
in AD pathogenesis, while neuroﬁbrillary tangle formation
and neuronal cell death occur downstream in this amyloid
cascade [4–6]. Recent in vitro work has demonstrated that
beta-amyloid dimers (the major form of soluble oligomers
in the human brain) isolated from patients with AD induce
both the abnormal phosphorylation of tau that is charac-
teristic of AD and the degeneration of neurites, providing
furtherconﬁrmationofthepivotalroleofbetaamyloidinthe
pathogenesis of AD [7]. The search for a disease modifying
therapy—one that aﬀects underlying pathology and has a
measurable and long-lasting eﬀect on the progression of
disability—hasthusbeenaimedprimarilyatthestudyofbeta
amyloid.
The demonstration of disease modiﬁcation is best
supported by both clinical and biomarker endpoints. A
biomarker is an objectively measured characteristic that can
be evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic responses to a
therapeutic intervention [8]. Several potential biomarkers
have been identiﬁed in AD and are currently under inves-
tigation in interventional clinical trials. These biomarkers
should be reﬂective of changes in the pathology of the AD
brain, such as cerebral beta-amyloid deposition, abnormal
phosphorylation of tau, or neurodegeneration.2 International Journal of Alzheimer’s Disease
Recentadvances in positron emission tomography (PET)
imaging have made possible the in vivo detection and quan-
tiﬁcation of beta amyloid using amyloid-speciﬁc ligands,
such as the 11C Pittsburgh Compound B (PiB) [9, 10].
Elevated levels of tau protein in the cerebrospinal ﬂuid (CSF)
are markers of active neuronal degeneration [11], while
levels of abnormally phosphorylated tau (P-tau) appear to
correlate with the quantity of neuroﬁbrillary tangles in the
brain, suggesting that CSF P-tau may serve as an in vivo
biomarker of the neuroﬁbrillary pathology of AD [12].
Magnetic resonance imaging (MRI)- based measures of
cerebral atrophy, most likely the result of excessive neuronal
death, correlate closely with the rate of neuropsychological
declineinpatientswithAD[13].Theseandotherbiomarkers
will likely play an important role in demonstrating the eﬀect
of any therapy on cerebral amyloid and the downstream
processes that are aﬀected through beta-amyloid removal.
2. Activeand PassiveImmunotherapeutic
Approachesto Beta-Amyloid Clearance
W h i l en u m e r o u ss t r a t e g i e sh a v eb e e nd e v e l o p e dt ol i m i t
cerebral beta-amyloid deposition and/or facilitate beta-
amyloid clearance, the most extensive preclinical and clinical
experience to date has come from immunotherapeutic
approaches, which can be broadly classiﬁed as either active
or passive (Figure 1).
Passive immunotherapy refers to the direct admin-
istration of anti-beta-amyloid antibodies, obviating the
need for patients to mount an antibody response. Pas-
sive immunotherapy in the form of speciﬁcally designed
monoclonal antibodies allows for the precise targeting of
beta-amyloid epitopes. In contrast, active immunother-
apy involves the administration of either full-length beta-
amyloid peptides or peptide fragments to activate the
patient’s immune system in order to produce anti-beta-
amyloid antibodies. The beta-amyloid peptides or peptide
fragments can be conjugated to a carrier protein and may
be administered with an adjuvant in order to help stimulate
the immune response. As active immunotherapy relies on
the patient’s own immune response, the extent and nature
of anti-beta-amyloid antibody production is likely to vary
among individuals, and some patients may not be able to
mount a meaningful antibody titer. Active immunotherapy
can induce an oligoclonal (as opposed to monoclonal)
response with antibodies that diﬀer with respect to their
binding aﬃnity for a number of toxic beta-amyloid species.
Unlike passive immunotherapy, which has to be readmin-
istered at frequent intervals, active immunotherapy has the
potential to produce persistent levels of anti-beta-amyloid
antibody titers with less-frequent administration.
3. Insightsfrom PreclinicalStudies
An extensive body of preclinical work (summarized brieﬂy
here and reviewed more extensively elsewhere) [14]p r o -
vides support for an immunotherapeutic approach to beta-
amyloid lowering in AD. In 1999, Schenk et al. published
a seminal study demonstrating that the administration of
beta amyloid42 prevented beta-amyloid plaque formation in
platelet-derivedgrowthfactorpromoter(PDAPP)transgenic
mice, a mouse model which overexpresses human amyloid
precursor protein [15]. Animals treated with this active
immunotherapy also demonstrated a marked attenuation in
neuritic dystrophy and astrogliosis [15]. Older mice that had
already developed some neuropathologic changes at the time
of treatment showed a reduction in AD-like neuropathology
as compared with older nontreated controls [15]. Schenk’s
pathology-focused work was followed by the demonstration
that beta-amyloid vaccination protected “double transgenic”
(APP+PS1)micefromdevelopingthelearningandmemory
deﬁcits that normally occurred in this animal model [16].
Vaccinateddoubletransgenicmiceperformedaswellasnon-
transgenic controls on the radial-arm water-maze test, sug-
gesting that vaccination may have the potential to restore the
wildtypephenotype.Theabilityofbeta-amyloidvaccination
to attenuate beta-amyloid pathology and behavioral deﬁcits
has also been demonstrated in other transgenic models [17].
In parallel with the active immunotherapeutic ap-
proaches described above, preclinical studies utilizing pas-
sive immunotherapy spearheaded by Bard et al. established
that peripherally administered anti-beta-amyloid antibodies
enterthecentralnervoussystemandbindtoamyloidplaques
in PDAPP mice, resulting in a plaque reduction of up to 86%
as compared with untreated controls [18]. Plaque clearance
was shown to occur through fragment crystallizable (Fc)
receptor-mediated phagocytosis by microglial cells, with
no evidence of T-cell response activation [18]. Additional
work by Wilcock et al. conﬁrmed that administration of
anti-beta-amyloid antibodies resulted in the activation of
brain microglia (as evidenced by microglial expression of
CD45 and the FcΥ receptor), reduced brain beta-amyloid
deposits,andimprovedperformanceontheY-mazebehavior
task in APP transgenic mice [19]. Recent in vitro ﬁndings
demonstrate that antibodies directed at the N-terminal of
beta amyloid neutralize the cytoskeletal alterations that are
induced by beta-amyloid dimers [7] and that the murine
form of bapineuzumab (3D6) interacts with soluble beta-
amyloidspecies.Themurineformofbapineuzumabwasalso
eﬀective at neutralizing several in vitro and in vivo measures
of synaptotoxicity in preclinical models [20].
Although Fc receptor-mediated phagocytosis is believed
to play a role in immunotherapy-induced beta-amyloid
clearance, other studies have demonstrated that Fc recep-
tor interactions are not necessarily required for beta-
amyloid removal [21, 22]. These experiments suggest that
other mechanisms may also be involved in the antibody-
mediated clearance of beta amyloid with active and passive
immunotherapy. One of these proposed mechanisms specu-
lates that anti-beta-amyloid antibodies exert their eﬀect not
in the brain but rather in the periphery, where they bind
to circulating beta-amyloid molecules and reduce the free
concentration of beta amyloid in the blood. According to
this “peripheral sink” hypothesis, the equilibrium across the
blood-brain barrier is then altered to favor the next eﬄux
of beta amyloid from the brain [23]. Another hypothesis
proposes that the binding of anti-beta-amyloid antibodies to
the beta-amyloid molecule alters its conformation so that itInternational Journal of Alzheimer’s Disease 3
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Figure 1: Passive and active immunotherapeutic approaches to beta-amyloid clearance. Beta-amyloid immunotherapeutic compounds
currently in clinical trials utilize anti-beta-amyloid antibodies, generated through either passive or active immunotherapy approaches (left),
to target beta amyloid and promote its clearance from the brain and proteolysis (right), potentially reversing the neuropathology that leads
to cognitive dysfunction. Aβ: beta amyloid.
is less likely to form the ﬁbrillar aggregates associated with
AD pathology [24].
Preclinical data is also available for human intravenous
immunoglobulin (IVIG). Magga et al. demonstrated that
peripherally administered IVIG penetrated the blood-brain
barrier and bound to beta-amyloid deposits in mouse brain
[25]. In addition, IVIG obtained from the plasma of healthy
human volunteers protected mouse hippocampal neurons
from beta-amyloid toxicity in vitro [25]. The eﬀects of IVIG
may be due in large part to the presence of naturally occur-
ring anti-beta-amyloid antibodies, which are abundant in
human plasma but decline with age and advancing AD [26].
Numerous other mechanisms of action have been proposed
for IVIG, including complement binding, interference with
B-cell diﬀerentiation, and cytokine modulation [27].
4. ClinicalTrialswith ActiveImmunotherapy
4.1. AN1792
4.1.1. Phase 1 Trial. Following on the promising preclinical
results described above, AN1792, a synthetic beta-amyloid
peptide, was the ﬁrst active amyloid immunotherapy tested
in clinical trials [28]. The initial study randomized 80
subjects with mild-to-moderate AD; 64 subjects received
AN1792 with QS-21 (adjuvant) and 16 received QS-21
alone [28]. Injections were administered 4 times over a 24-
week period, with an optional extension phase that allowed
subjects to receive up to 4 additional injections over a total
follow-up time of 84 weeks [28].
Of the 64 subjects who received AN1792, 53% developed
a positive anti-AN1792 antibody response (deﬁned as an
antibody titer ≥1:1,000) at one or more points during the
trial [28]. Exploratory eﬃcacy analyses showed no diﬀerence
between rates of cognitive decline in treated and control
groups as measured by the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-cog) and Mini-Mental State Exam-
ination (MMSE) [28]. At week 84, however, patients who
had received AN1792 showed less functional decline (as
measuredbytheDisabilityAssessmentforDementia[DAD])
than those treated with QS-21 alone (adjusted mean values
−14.15 versus −36.42, P<0.002) [28].
Although the vast majority of adverse events (AEs)
reported during the initial study were either mild or mod-
erate in nature, one patient treated with AN1792 developed
severe dizziness, disorientation, and functional deterioration
[28]. This patient died approximately 1 year after her ﬁfth
and ﬁnal injection of AN1792, and a few weeks after dose
administration in the phase 2a trial was halted due to
cases of meningoencephalitis (see below) [28]. The patient’s
postmortem examination revealed changes consistent with
T-lymphocytic meningoencephalitis and was also signiﬁcant
for extensive cortical areas devoid of beta-amyloid plaques
[29].
4.1.2. Phase 2a Trial and Meningoencephalitis. The phase
2a study of AN1792 in mild-to-moderate AD randomized
300 patients to receive AN1792 (QS-21) and 72 patients to
receive placebo [30]. Dosing was halted after 18 AN1792
(QS-21)-treated patients (6% of all patients who received
active therapy) developed aseptic meningoencephalitis [30].
AN1792-associated meningoencephalitis was variable with
respect to clinical presentation, severity, and resolution.
Most patients developed progressive confusion, lethargy, and
headache [31]. Other reported signs and symptoms included
fever, nausea, vomiting, seizures, and focal neurologic signs
[31].Meningoencephalitisdevelopedfrom5to168daysafter
the last injection of AN1792, with a median latency of 40
days [31]. While most patients experienced a monophasic
illness, 4 patients developed a relapse following the initial
resolution of meningoencephalitis, and 2 of these relapses
were severe [31]. Recovery was reported in 12 of the 184 International Journal of Alzheimer’s Disease
patients, while 6 patients were noted to have persistent
sequelae at the conclusion of the trial [31]. No additional
cases of meningoencephalitis were reported over a 4.6-year
follow-up study of subjects previously enrolled in the 2a
trial [32]. No cases of meningoencephalitis occurred in the
placebo-treated patients [31, 32].
Geometric mean serum anti-AN1792 antibody titers
werenotsigniﬁcantlyhigherinthosepatientswhodeveloped
meningoencephalitis than in those who did not [30]. Five
of the 18 patients with meningoencephalitis did not meet
the antibody responder criterion (deﬁned here as a serum
anti-AN1792 IgG [total] titer ≥1:2,200 at any time after
injection), and one patient with meningoencephalitis had
serum IgG titers <1:50 over the entire study course [30]. No
correlationwasestablishedbetweenantibodytitersandtime-
to-symptom onset, severity of illness, or relapse [31].
MRI ﬁndings in patients with meningoencephalitis were
alsovariable,rangingfromsubtlemeningealenhancementto
cerebral edema and extensive parenchymal signal abnormal-
ities with a predominantly posterior distribution [31]. No
hemorrhagic ﬁndings (such as microhemorrhages or larger
hemosiderin deposits) were reported [31]. CSF analysis was
performed in 17 of the 18 cases; 16 of these revealed a
lymphocytic pleocytosis, with WBC counts ranging from 15
to 130cells/mL, and CSF protein from 0.33 to 3.1g/L (33–
310mg/dL) [31] .G l u c o s el e v e l sw e r ew i t h i nn o r m a ll i m i t s
[31]. IgG levels were elevated in 3 of 4 patients tested, and
oligoclonal bands were reported in 2 of the 18 cases [31].
One possible factor in the development of meningoen-
cephalitis (which had not occurred in preclinical studies) in
this subset of AN1792 (QS-21)-treated patients stems from
the introduction of polysorbate 80 into the formulation [30].
Atthelatestagesofthephase1trialdescribedabove,polysor-
bate 80 was added to prevent AN1792 (QS-21) precipitation
[29]. The single subject who developed meningoencephalitis
in the phase 1 study did so approximately 36 days after
receiving the ﬁfth dose of AN1792 (QS-21), which was
also the ﬁrst dose using the altered formulation [29]. It is
possible that the addition of polysorbate 80 resulted in an
increased exposure of amyloid-beta1−42 amino acids to epi-
topes capable of mounting an inﬂammatory T-cell response
[30, 33]. Peripheral blood mononuclear cell isolates from
patients who received AN1792 were analyzed for cytokine
response to beta-amyloid-derived peptides using enzyme-
linked immunosorbent spot (ELIspot) assays. These assays
showed a diﬀerence in the quality of the T-cell response
induced by the two diﬀerent formulations of AN1792,
with isolates from patients who received the polysorbate
80-containing formulation more likely to exhibit a beta-
amyloid-speciﬁc proinﬂammatory Th1 response. The speci-
ﬁcity of the antibody response did not diﬀer between the two
formulations and was directed almost exclusively to the N-
terminus [33]. Neuropathologic examination of one case of
meningoencephalitis revealed a perivascular T-cell inﬁltrate
with a lack of B lymphocytes, as well as microglial activation
andmultinucleatedgiantcells[34].Lymphocytedistribution
was most prominent in the temporal cortex, hippocampus,
and amygdale and did not match the observed distribution
of beta-amyloid clearance. Lymphocyte distribution did
appear to correspond with the ﬁnding of collapsed plaques,
which were characterized by abnormal morphology and
composed of dense amyloid cores surrounded by activated
microglial cells.This colocalization of lymphocytic inﬁltrates
andabnormal plaquesmay suggestthatmeningoencephalitis
was related to abnormal beta-amyloid processing and not to
beta-amyloid clearance [34].
4.1.3. Immunologic and Clinical Outcomes. At the time of
discontinuation of dosing due to meningoencephalitis, over
90% of patients in the phase 2a trial had received 2 of the
planned 6 injections of AN1792 (QS-21)/placebo [30]. The
study was amended to allow safety follow-up for at least
9 months after the last injection [30]. Despite the limited
number of administered injections, approximately 20% of
the subjects treated with AN1792 (QS-21) were classiﬁed as
antibody responders [30].
As expected, the AN1792 phase 2a study demonstrated
no diﬀerences between treatment groups in the majority of
the cognitive, functional, and global change scores, which
became exploratory measures when dosing was discontin-
ued [30]. However, the composite Neuropsychological Test
Battery (NTB) z-score, as well as other NTB component
scores including the memory scores, showed less worsening
in the antibody responder group compared with the placebo
group (P = 0.020) at month 12 [30]. Moreover, there was
a direct relationship between mean antibody titers and the
overall composite NTB z-score, as well as NTB z-scores
for all memory, immediate memory, and delayed memory,
indicating greater improvements from baseline in patients
with higher antibody titers [30].
The short-term results of the abbreviated phase 2a trial
must be viewed in the context of the long-term follow-up
study, which enrolled 159 of the patients who had originally
participated in the AN1792 phase 2a trial, including 25 anti-
body responders, 104 low/nonresponders, and 30 placebo-
treated patients [32]. Of the 19 antibody responders who
submitted a blood sample for testing, 17 (89.5%) demon-
strated a persistently positive anti-AN1792 antibody titer
approximately 4.6 years after their last injection of AN1792
[32]. Although these titers were low (geometric mean of
1:331.5),theyseemedsuﬃcienttoprovidemeaningfullong-
termbeneﬁtsinsomeoftheeﬃcacyﬁndingsthatwereexam-
ined in this population [32]. As compared with placebo-
treated patients, antibody responders had a 25% lower
decline in activities of daily living as assessed by the DAD,
a reduction in decline on the Rey Auditory Verbal Learning
component of the NTB, and 20% less decline on the Clinical
Dementia Rating Scale Sum of Boxes (CDR-SOB) [32].
The diﬀerences between placebo-treated patients and anti-
body responders were statistically signiﬁcant for the ﬁrst 2
of these assessments (P = 0.015 and P = 0.046, resp.) [32].
After approximately 4.6 years of follow-up, 76% of antibody
responders were living in their own home and 16% were
living in long-term care institutions; the percentages for
placebo-treated patients were 53% and 30%, respectively
[32]. On the Dependence Scale, antibody responders had a
17.6% lower mean score in caregiver dependence comparedInternational Journal of Alzheimer’s Disease 5
withplacebo-treatedpatients(P = 0.033).Nosigniﬁcantdif-
ferences between antibody responders and placebo-treated
patients were noted on the composite NTB z-score, the
MMSE, or the ADAS-Cog [32].
It is important to note that while the dependence
measures (such as DAD and institutional status) could be
assessed based on caregiver input, cognitive measures had
to be obtained from patients directly [32]. Many patients in
the long-term follow-up study were unable or unwilling to
provide responses to these cognitive assessments, resulting in
a proportionally higher percentage of missing data for these
endpoints, as compared with the functional scales [32]. The
extent of missing functional data may have contributed to
the lack of clear placebo/treatment diﬀerences on cognitive
endpoints [32].
4.1.4. Biomarkers. Along with the potential clinical eﬃ-
cacy signals described above, several important biomarker
changes were observed in the AN1792 phase 2a trial. Ten
antibody responders and 11 placebo-treated patients under-
went pre- and postbaseline CSF analysis [30]. A statistically
signiﬁcant reduction in CSF tau was seen in the antibody
responder group, but there was no treatment eﬀect on CSF
beta-amyloid levels [30].
Baseline and post-treatment brain MRI scans (obtained
either at month 12 or at early termination) were available
for 288 of the 372 patients who participated in the study,
and were used to determine whole-brain, ventricular, and
hippocampal volumes [35]. The change in whole-brain
boundary shift interval (BSI) over the treatment period was
greater in the antibody responders than in the placebo group
(P = 0.007), indicating a greater loss of brain volume in the
antibody responder group [35]. Antibody responders also
had a signiﬁcantly greater increase in ventricular volume
thanplacebo-treatedpatients(P<0.001)[35].Anti-AN1792
IgGserumtiterscorrelatedwiththepercentchangeinwhole-
brain BSI (Pearson correlation coeﬃcient r = 0.293; P =
0.003) and ventricular BSI (r = 0.472; P<0.0001) in treated
patients who had titers ≥1:100 [35].
Both placebo-treated patients and antibody responders
exhibited a decrease in hippocampal volumes over the study
period, with no signiﬁcant diﬀerence between the 2 groups
[35]. Whole-brain, ventricular, and hippocampal volumes in
nonresponders did not diﬀer from those of placebo-treated
patients [35]. The AN1792 follow-up study [32] showed no
signiﬁcantdiﬀerenceinwhole-brainorhippocampalvolume
changes from baseline between antibody responders and
placebo-treatedpatientsatameanfollow-upof4.6years,but
thenumberofpatients forwhomMRIdatawasavailablewas
small. The antibody responders, however, showed a greater
increase in ventricular volume than that seen in placebo-
treated patients (P = 0.021) [32].
The etiology and clinical signiﬁcance of the above-
described changes in MRI-measured brain and ventricular
volumes remains unclear. The suggestion that AN1792
caused an accelerated rate of neurodegeneration in antibody
responders is unsupported, given the lack of worsened
clinical decline (and in light of the potential signals of
clinical beneﬁt) in patients who developed positive titers
[35]. An alternative explanation is that at least some of the
cerebral volume loss can be accounted for by the removal
of beta-amyloid plaques in antibody responders and/or by
parenchymal/CSF ﬂuid shifts that may have occurred in
parallel with shifts in beta amyloid [35]. The latter two
hypotheses are now supported by multiple autopsy cases that
have been performed on AN1792 responders, which clearly
demonstrate eﬀective beta-amyloid clearance (see below).
4.1.5. Pathologic Findings. In 2006, Nicoll et al. published
the neuropathologic ﬁndings of 3 patients who had received
between 2 and 5 doses of AN1792 (QS-21) [36]. Two of the 3
cases were known to have developed anti-beta-amyloid anti-
bodiesoverthecourseofthestudy,andbothofthesepatients
also developed meningoencephalitis [36]. The causes of
death in the autopsied cases, however, were nonneurologic
in nature (pulmonary embolism, bronchoaspiration, and
abdominal aortic aneurysm) [36]. Nicoll et al. compared the
ﬁndings in the AN1792 (QS-21)-treated cases to 7 untreated
cases that met neuropathologic criteria for AD [36].
A marked reduction in beta-amyloid plaque deposition
was noted in the temporal cortex of the 2 AN1792 (QS-21)
cases that had developed anti-beta-amyloid antibodies: 69%
and 89% of the temporal cortex was classiﬁed as plaque-
free, as compared with <1% in control cases [36]. Plaque
removal appeared patchy, with a relatively higher plaque
density in the frontal lobes [36]. The antibody nonresponder
case demonstrated no plaque-free areas in the temporal
and medial frontal cortex but showed some patchy areas of
plaqueremovalelsewhere[36].Morphologicstudiesrevealed
furtherevidenceofplaqueclearanceinall3immunizedcases
and demonstrated the presence of beta-amyloid granules
within lysosomes and activated microglia [36]. Beta amyloid
with an intact N-terminus had been cleared eﬀectively, while
beta-amyloid species truncated at the N-terminus persisted
[36].
Although both antibody-positive subjects in this series
also had a history of meningoencephalitis [36], other
neuropathologic examinations have demonstrated plaque
clearance in subjects without meningoencephalitis [37]. In
contrast to cortical amyloid, vascular amyloid was not
removed by active immunization, as all 3 autopsy cases
had severe cerebral amyloid angiopathy (CAA) at autopsy
[36]. This ﬁnding has been conﬁrmed by Patton et al., who
examined 2 AN1792-immunized patients and noted that
while both compact core and diﬀuse amyloid deposits were
diminished, vascular deposits were relatively preserved or
even increased [38].
Importantly,theworkofNicolletal.showedthatplaque-
free cortical regions also exhibited a decrease in the density
of dystrophic neurons, although there was no clear evidence
of an impact on neuronal tau or neurophil threads [36].
The downstream eﬀects of beta-amyloid immunization were
further elucidated by Serrano-Pozo et al., who performed
detailed quantitative analyses of hippocampal sections from
AN1792-treated patients and compared these with samples
from nondemented controls and untreated patients with
AD [39]. In addition to the expected clearance of beta-
amyloid plaques in immunized patients, Serrano-Pozo et al.6 International Journal of Alzheimer’s Disease
demonstrated the normalization of neurite morphology and
a signiﬁcant reduction in the hyperphosphorylation of tau
[39]. The ability of AN1792 to reduce tau hyperphosphory-
lation has also been reported elsewhere [34].
While the neuropathologic ﬁndings discussed above pro-
vide compelling evidence for the beneﬁcial eﬀects of active
beta-amyloid therapy on both beta-amyloid plaque burden
and the downstream eﬀects of beta-amyloid pathology, the
clinical signiﬁcance of beta-amyloid clearance has been
challenged by other autopsy studies. Holmes et al. published
long-term ﬁndings of AN1792-treated subjects up to 5 years
after the last injection of AN1792 [40]. When compared
with placebo-treated subjects who had also consented to
long-term follow-up, immunization had no eﬀect on long-
term survival or clinical outcomes, although the number
of subjects was small [40]. Eight AN1792-treated patients
with AD consented to autopsy, which demonstrated a long-
t e r mr e d u c t i o ni nm e a nb e t a - a m y l o i dl o a da sc o m p a r e d
with untreated controls [40]. Seven of these 8 patients,
2 of whom had nearly complete beta-amyloid removal at
autopsy, also had severe end-stage dementia at the time
of death, leading the authors to conclude that progressive
neurodegeneration had occurred despite eﬀective clearance
of beta amyloid [40]. It is important to point out, however,
that the neuropathologic examinations performed in this
sample included only those patients who died, and the
ﬁndings are therefore not generalizable to those treated
patients who survived. As such, the results of this study are
in direct conﬂict with those reported by Vellas et al., who
demonstrated a long-term clinical beneﬁt with AN1792 [32].
4.2. Active Immunotherapies Currently in Clinical Trials.
While studies with AN1792 were discontinued due to the
occurrence of meningoencephalitis, the trials paved the
way for the many active immunotherapeutic clinical trials
currently in progress (Table 1 and Figure 1). In a study of
serum samples from patients immunized with AN1792, Lee
et al. established that the predominant antibody response
in these patients was against the free N-terminus of beta
amyloid; speciﬁcally, against beta amyloid1−8 [41]. Vanutide
cridiﬁcar (ACC-001) is a conjugate of multiple copies of
beta-amyloid1−7 peptide linked to a nontoxic variant of
diphtheria toxin [42]. Preclinical data indicate that vanutide
cridiﬁcar generates N-terminal anti-beta-amyloid antibodies
without inducing a beta-amyloid-directed T-cell response,
and that it reverses cognitive impairment in murine
models of AD [42]. Vanutide cridiﬁcar is currently
in phase 2 clinical trials in mild-to-moderate AD and
early AD (NCT01284387; NCT01227564; NCT00479557;
NCT00955409;NCT00498602;NCT00752232;NCT01238991;
NCT00960531; NCT00959192). Other active immunother-
apies currently under study include CAD106 (Novartis,
Inc.), V950 (Merck & Co.), and AD02 (AFFiRiS AG/
GlaxoSmithKline plc).
4.2.1.CAD106. CAD106iscomposedofthebeta-amyloid1−6
peptide coupled with a Qβ carrier [43, 44]. A 52-week study
with CAD106 included 58 patients with mild-to-moderate
AD in 2 cohorts: 50μg CAD106 or placebo administered
at weeks 0, 6, and 18 (cohort 1); or 150μg CAD106 or
placebo at weeks 0, 2, and 6 (cohort 2) [43, 44]. Injection-
site erythema was the most frequent AE observed with
CAD106 (4% in cohort I; 64% in cohort II); most AEs
were mild, and serious AEs were considered unrelated to
study medication [43, 44]. CAD106 was associated with an
antibody response in 16/24 treated patients in cohort 1 and
18/22 patients in cohort 2 [43, 44]. In 2 52-week, phase 2a
studies in 58 patients with mild AD, 150μg CAD106 was
administered subcutaneously at weeks 0, 6, and 12 (study
1), or either subcutaneously or intramuscularly at weeks 0,
2, and 6 (study 2) [45]. Results of study 1 showed antibody
response in 20/22 patients. Because the results indicated that
week2injectiondidnotenhanceantibodyresponse,a0/6/12
week regimen was selected for further study [45]. Two phase
2 studies currently in progress are investigating repeated
administration of CAD106 intramuscularly (NCT01097096)
or subcutaneously (NCT00956410; NCT01023685).
4.2.2. V950. V950 is a multivalent beta-amyloid vaccine
[46].Todate,noclinicaldatahavebeenpresented.Preclinical
studieshaveshownthatadministrationofV950resultsinthe
productionofanti-beta-amyloidantibodiesintheserumand
CSF that recognize pyroglutamate-modiﬁed and other N-
terminally truncated beta-amyloid fragments [46]. A phase
1 study of V950 in patients with AD is currently underway
(NCT00464334).
4.2.3. AFFITOPE AD02. AFFITOPE AD02 is composed of a
6-amino acid peptide that mimics part of the N-terminus of
beta amyloid [47]. It is hypothesized that AD02 and other
active immunotherapeutic approaches using this technology
m a yh a v eaf a v o r a b l es a f e t yp r o ﬁ l eb e c a u s et h e ya r en o n s e l f
andthusdonotneedtoovercometolerance—theirsmallsize
prevents autoreactive T-cell activation, and their controlled
speciﬁcity prevents cross-reactivity with amyloid precursor
protein [48]. Phase 1 data showed a favorable safety proﬁle
with AD02 and AD01, another AFFITOPE compound [48].
A randomized, multicenter, phase 2 trial with AD02 in
patients with early AD is currently recruiting participants
(NCT01117818).
5. ClinicalTrialswithPassiveImmunotherapy
Passive immunotherapeutic approaches to AD are being
investigated in parallel with the active therapies described
above. To date, the largest quantity of published data on
passive immunotherapy pertains to bapineuzumab, which
is being codeveloped by Pﬁzer Inc. and Janssen Alzheimer
Immunotherapy Research & Development, LLC.
5.1. Bapineuzumab
5.1.1. Phase 1 Trial. Bapineuzumab is a humanized mono-
clonal antibody that targets the N-terminal region of beta
amyloid [49] (Figure 1). Bapineuzumab at doses of 0.5, 1.5,
or 5mg/kg was ﬁrst tested in patients with mild-to-mod-
erate AD in a 12-month, single ascending-dose study [49].International Journal of Alzheimer’s Disease 7
Table 1: Active immunotherapy agents.
Drug name Sponsor(s) Mechanism of action Status Key clinical data
Source of
key clinical
data
ACC-001
(vanutide
cridiﬁcar)
JANSSEN Alzheimer
Immunotherapy Research &
Development, LLC.; Pﬁzer Inc.
Multiple copies of Aβ1−7 peptide
linked to a nontoxic variant of
diphtheria toxin
Phase 2 No clinical data have
been presented to date —
AD02 AFFiRiS AG
Short (6 aa) peptide mimicking
parts of the native Aβ
N-terminus sequence
Phase 2
Phase 1 safety data
support
proof-of-concept for
improved safety proﬁle
using AFFITOPE
technology
[48]
CAD106 Novartis, Inc. Aβ1−6 peptide coupled with Qβ
carrier Phase 2
In a phase 2a study,
CAD106 showed a
favorable safety proﬁle
and antibody response
in 20/22 patients with
mild AD
[45]
V950 Merck & Co. Multivalent Aβ vaccine Phase 1 No clinical data have
been presented to date —
Aβ: beta amyloid; AD: Alzheimer’s disease.
The majority of treatment-emergent AEs were mild to mod-
erate in severity and were not considered related to treat-
ment by study investigators [49]. The phase 1 study in-
cluded protocol-speciﬁed periodic MRI monitoring, and
MRI abnormalities consistent with vasogenic edema were
reported in 3 of the 10 patients randomized to bapineuz-
umab 5.0mg/kg [49]. Recently published recommendations
from the Alzheimer’s Association Research Roundtable
Workgroup include the use of the term amyloid-related
imaging abnormalities (ARIA) in reference to the spec-
trum of imaging ﬁndings associated with amyloid-lowering
therapies and ARIA-edema/eﬀusions (ARIA-E) to refer to
ﬁndings previously referred to as “vasogenic edema” [50].
The authors have chosen to adopt this terminology for
the purposes of this paper. The MRI ﬁndings in the
bapineuzumab study consisted of hyperintensities on ﬂuid-
attenuated inversion recovery (FLAIR) sequences [49]. In
one of the 3 cases, the FLAIR abnormality was accom-
panied by the development of a new microhemorrhage
[49]. The MRI abnormalities, with the exception of the
microhemorrhage, resolved in all 3 cases over a period
of weeks to months [49]. Two of the 3 patients with
ARIA-E were asymptomatic, and one patient experienced
mild and transient confusion [49]. Two of the 3 patients
with ARIA-E underwent CSF analysis. In contrast to the
meningoencephalitis cases reported with AN1792, CSF was
acellular in both cases, with minor elevations in CSF protein
(58.5 and 59.8mg/dL) [49].
Plasma levels of bapineuzumab increased over 1-2 hours
following an infusion, and plasma half-lives ranged from 21
to 26 days [49]. MMSE was performed as an exploratory
eﬃcacy measure, and mean MMSE increased from baseline
over the course of the trial at the 0.5 and 1.5mg/kg
bapineuzumab doses (except for month 6 at the 1.5mg/kg
dose) [49]. Mean MMSE decreased in patients on placebo
except at month 6 and also decreased in patients who
received 5.0mg/kg of bapineuzumab [49]. At the primary
time point (week 16), at the 1.5mg/kg dose, the treatment
versus placebo diﬀerence in MMSE (2.6) was statistically
signiﬁcant (P = 0.047) in favor of bapineuzumab [49].
5.1.2. Phase 2 Trial. The phase 1 study was followed by
a multiple ascending dose trial in which 124 patients
with mild-to-moderate AD were randomized to 1 of 4
doses (0.15, 0.5, 1, or 2mg/kg) of bapineuzumab, and 110
patients received placebo [51]. Study assessments consisted
of numerous clinical evaluations (including the ADAS-
Cog, NTB, and DAD), safety, tolerability, and biomarkers,
including CSF and brain volume [51]. Bapineuzumab or
placebo infusions were given every 13 weeks for up to 78
weeks [51]. In the prespeciﬁed eﬃcacy analyses (within-
dose-cohort diﬀerences between bapineuzumab and placebo
from baseline to week 78), no signiﬁcant diﬀerence was seen
in any of the cohorts on either of the pre-speciﬁed primary
outcomes (ADAS-Cog or DAD). Exploratory analyses on
the overall treatment groups (pooled bapineuzumab versus
placebo)revealedtrendsontheADAS-CogandNTB,butnot
on the DAD or other outcomes [51]. Treatment diﬀerences
in ADAS-Cog, NTB, and DAD became more apparent when
analyses were carried out on the “completer” population
[51].
Post-hoc exploratory eﬃcacy analyses were also carried
out by apolipoprotein E ε4 (ApoE4) carrier status, following
the observation that ARIA-E was more common in ApoE4
c a r r i e r s( s e eb e l o w )[ 51]. In the 79 ApoE4 noncarriers,
bapineuzumab/placebo treatment diﬀerences were observed
in several outcomes, including the ADAS-Cog and the NTB,
although there was no diﬀerence on the DAD [51]. No8 International Journal of Alzheimer’s Disease
treatment diﬀerences were observed on any of the endpoints
in the 146 ApoE4 carriers although potential eﬃcacy signals
became apparent in analyses limited to those ApoE4-positive
patients who completed the trial [51]. In general, treatment
diﬀerences began to emerge at approximately month 9 of the
trial [51].
The bapineuzumab phase 2 trial included CSF biomark-
ers and MRI volumetric endpoints. CSF samples were ob-
tained in 35 study subjects. There were no observed treat-
ment diﬀerences in either CSF beta amyloid or total tau
levels, but there was a trend towards greater reduction in P-
tau in bapineuzumab-treated patients when compared with
placebo (δ =− 9.1pg/mL; 95% CI, 18.5–0.3; P = 0.056)
[51]. In a subsequently conducted exploratory pooled anal-
ysis including patients from the PET PiB study (described
below),whencomparingthechangefrombaselinetoend-of-
studyCSFP-tauvalues,asigniﬁcanttreatmentreductionwas
observed in the bapineuzumab-treated patients compared
with patients who received placebo (−7.26pg/mL, P =
0.0270) [52].
No overall diﬀerences between combined bapineuzumab
and placebo-treated patients were observed with respect to
whole-brain and ventricular volumes as measured by MRI
volumetric analyses over 18 months [51]. However, ApoE4
noncarriers treated with bapineuzumab showed less brain
volume loss than those on placebo (δ =− 10.7mL; 95% CI,
3.4–18.0; P = 0.004) [51]. No diﬀerences in brain volume
were noted in ApoE4 carriers, but the bapineuzumab group
had a greater increase in ventricular enlargement than the
placebo-treated subjects (δ = 2.6mL; 95% CI, 0.2–5.0; P =
0.037) [51].
The most common AEs (reported in >5% of bap-
ineuzumab patients and occurring at a rate of at least twice
that of placebo) included ARIA-E, back pain, anxiety, and
paranoia. Other AEs which also occurred more frequently
in the bapineuzumab group included deep vein thrombosis,
syncope, seizures, vomiting, hypertension, weight loss, skin
laceration, gait disturbance, muscle spasm, and pulmonary
embolism [51].
ARIA-E, which was noted in the phase 1 trial, was
detected in 12 of the 124 bapineuzumab-treated subjects
(9.7%) and none of the placebo-treated subjects in the phase
2s t u d y[ 51]. As was true in the earlier study, ARIA-E was
more likely to occur at higher bapineuzumab doses, with
rates of 3.2%, 0%, 10%, and 26.7% for the 0.15mg/kg,
0.5mg/kg, 1mg/kg, and 2mg/kg doses, respectively [51].
Eleven of the 12 cases of ARIA-E were detected following
either the ﬁrst or second bapineuzumab infusion [51]. Six of
the patients with ARIA-E had no clinical symptoms, while 6
patientsexperiencedsymptomssuchasheadache,confusion,
vomiting, and gait disturbance [51]. These symptoms were
transient although one patient required treatment with
steroids [51]. The MRI ﬁndings in these ARIA-E cases
were consistent with those described in the earlier trial
and resolved over a period of several months [51]. The
clinical and MRI characteristics of bapineuzumab-associated
ARIA-E, along with the lack of evidence of inﬂammation
as illustrated by the CSF ﬁndings described above, diﬀer-
entiate bapineuzumab-related ARIA-E from the severe cases
of meningoencephalitis that occurred in association with
AN1792.
One of the most unexpected ﬁndings in the bap-
ineuzumab phase 2 study was the increased rate of ARIA-
E in ApoE4 carriers. Ten of the 12 ARIA-E cases occurred
in ApoE4 carriers, and the ARIA-E rates in ApoE4 car-
riers and noncarriers were 13.5% and 4.3%, respectively
[51]. Moreover, among ApoE4 carriers, the rate of ARIA-
E increased with the gene dose, with rates of 7.1% in
ApoE4 heterozygotes and 33.3% in ApoE4 homozygotes
[51]. These ﬁndings are particularly intriguing in light of
thepotentialApoE4-dependenteﬃcacydiﬀerencesdiscussed
above, and may be due at least in part to the increased
load of beta amyloid in ApoE4 carriers, including a higher
vascular beta-amyloid burden [51, 53]. It should be noted
that the prevalence of the ApoE4 allele appears to vary by
geographic location. An estimated 37–43% of Asian and
southern European/Mediterranean AD patients are ApoE4
carriers, compared with 58% of patients in North America
and 64% in northern Europe [54].
Although its mechanism is unknown, ARIA-E may result
from transient increases in cerebral vascular permeability
secondary to vascular amyloid clearance [51]. This theory is
supported by reports of spontaneously occurring amyloid-
related imaging abnormalities similar to those seen in the
bapineuzumab trials [55, 56].
5.1.3. Positron Emission Tomography (PET) Carbon-11-
Labelled Pittsburgh Compound B (11C-PiB) Study. The abil-
ity of bapineuzumab to clear cerebral beta amyloid was
demonstrated in vivo in a trial of patients with mild-to-
moderate AD who underwent serial PET scans with carbon-
11-labelled Pittsburgh compound B (11C-PiB) [57]. PiB is
known to bind to aggregated ﬁbrillar beta-amyloid deposits
and is therefore a marker of ﬁbrillar beta-amyloid load
[9,58].PiBalsobindstocerebrovascularamyloid[59].Inthe
trial, 20 patients were randomized to bapineuzumab at 1 of 3
doses (0.5, 1.0, or 2.0mg/kg) for a total of up to 6 infusions,
13weeksapart;8patientsreceivedplacebo[57].Theprimary
outcome measure for the trial was the diﬀerence between the
pooled bapineuzumab groups and the placebo group in the
mean change (from screening to week 78) in the 11C-PiB
corticaltocerebellarretentionratio[57].Thecerebellumwas
used as a reference region because it exhibits a relatively low
beta-amyloid load in AD [57].
By week 78, the estimated mean 11C-PiB retention ratio
decreased by 0.09 in the bapineuzumab group and increased
by 0.15 in the placebo group, with an estimated treatment
diﬀerence of −0.24 (95% CI,0.39 to −0.09; P = 0.003).
This ﬁnding correlates to an approximately 25% reduction
in cortical beta amyloid in bapineuzumab-treated patients
[57] (Figure 2). The extent of beta-amyloid reduction was
not clearly dose dependent [57]. Bapineuzumab/placebo
diﬀerences in 11C-PiB retention were statistically signiﬁcant
in all prespeciﬁed cortical regions (anterior and posterior
cingulate, frontal, temporal, parietal, and occipital cortex)
[57]. After adjustment for imbalances in baseline clinical
and 11C-PiB-bindingcharacteristics,therewerenotreatmentInternational Journal of Alzheimer’s Disease 9
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Figure 2: Positron emission tomography (PET) carbon-11-labelled Pittsburgh compound B (11C-PiB) images from patients treated with
bapineuzumab and those given placebo [57]. Reprinted from [57] with permission from Elsevier. Changes from screening to week 78 in
patients treated with bapineuzumab (a, b) and in patients treated with placebo (c, d). Mean 11C-PiB PET changes are shown at the top center
of each panel for each patient. The scale bar shows the PiB uptake ratios relative to cerebellum by color. The scans before and after treatment
are from MRI coregistered images in the same plane.
diﬀerencesnotedonclinicalorbiomarkerendpointsbetween
the bapineuzumab and placebo groups [57].
5.2. Other Passive Immunotherapies Currently in Clinical
Trials. Building on the data presented above, a phase
3 program for bapineuzumab is currently in progress, com-
prised of 4 trials: 2 studies in ApoE4 carriers (NCT00575055;
NCT00676143) and 2 trials in ApoE4 noncarriers
(NCT00574132; NCT00667810). There is considerably less
published data available on other passive immunothera-
peutic approaches, which include solanezumab (Eli Lilly
and Company), ponezumab (Pﬁzer Inc.), gantenerumab
(Hoﬀmann-La Roche, Ltd.), BAN2401 (Eisai Co., Ltd.), and
intravenous immunoglobulin (Baxter International Inc. and
Octapharma AG). These compounds are described brieﬂy
below and in Table 2 (see also Figure 1).
5.2.1. Solanezumab. Solanezumab (LY2062430) is a human-
ized monoclonal antibody against the mid-domain of beta
amyloid [60]. In a study to assess the safety and tolerability
of single-dose solanezumab (0.5, 1.5, 4.0, or 10.0mg/kg)
in patients with mild-to-moderate AD, solanezumab was
associated with infusion reactions in 2 out of 4 patients
receiving the highest dose (10.0mg/kg) [60]. Serious AEs
were not considered to be related to the study medication
[60]. There was no evidence of inﬂammation based on MRI
or CSF white blood cells counts, and analysis of C-reactive
protein (CRP) in blood samples showed only isolated
elevations [60]. In a multicenter, multiple-dose, open-label
study in Japan, 33 patients with mild-to-moderate AD
received a 400mg dose of solanezumab intravenously every
w e e k ,e v e r y4w e e k s ,o re v e r y8w e e k s[ 61]. Most AEs were
mild to moderate; one severe event was reported but was
considered unrelated to the study medication [61]. There
werenoreportsofinfusionreactionsormeningoencephalitis
[61]. Studies examining biochemical biomarkers found that
plasma and CSF-amyloid1−40 and beta-amyloid1−42, plasma
pyro-Glu 3–42 beta-amyloid (N3pGluAβ), and plasma and
CSF N-terminally truncated beta-amyloid peptide (fragment
2), but not CSF total tau and phosphorylated tau (P-
tau181), exhibited signiﬁcant changes in patients receiving
solanezumab, indicating the utility of these biomarkers for
evaluatingthepharmacodynamiceﬀectsofsolanezumab[60,
62–66]. In addition, there was a correlation between plasma
beta-amyloid1−42 and assessment of amyloid burden using
single photon emission tomography with IMPY [64]. Three
phase 3 studies—2 evaluating the eﬀects of solanezumab
on disease progression, and one extension study mon-
itoring safety for participants in those studies—are in
progress (NCT00904683; NCT00905372; NCT01127633).10 International Journal of Alzheimer’s Disease
Table 2: Passive immunotherapy agents.
Drug name Sponsor(s) Mechanism of action Status Key clinical data
Source of
key clinical
data
Bapineuzumab
JANSSEN Alzheimer
Immunotherapy Research
&D e v e l o p m e n t ,L L C . ;
Pﬁzer Inc.
Humanized mAb that targets
the N-terminal region of Aβ Phase 3
No signiﬁcant diﬀerences
compared with placebo in
primary outcomes
(ADAS-Cog or DAD);
potential treatment
diﬀerences based on ApoE4
carrier status
[51]
IVIG (Gammagard) Baxter International Inc. Intravenous Ig; contains
antibodies against Aβ Phase 3
Signiﬁcant diﬀerences
compared with placebo in
primary outcome measures
(ADAS-Cog and
ADCS-CGIC)
[78]
Solanezumab Eli Lilly and Company
Humanized monoclonal
antibody against the
mid-domain of Aβ
Phase 3
Favorable safety proﬁle: no
evidence of
meningoencephalitis,
microhemorrhage, or
ARIA-E
[60]
Gantenerumab Hoﬀmann-La Roche, Inc. Monoclonal antibody that
targets Aβ Phase 2 No clinical data have been
p r e s e n t e dt od a t e —
IVIG (Octagam) Octapharma AG Intravenous Ig; contains
antibodies against Aβ Phase 2 No clinical data have been
p r e s e n t e dt od a t e —
IVIG (Newgam) Sutter Health Intravenous Ig; contains
antibodies against Aβ Phase 2 No clinical data have been
p r e s e n t e dt od a t e —
Ponezumab Pﬁzer Inc.
Humanized IgG2deltaA
monoclonal antibody that
binds to amino acids 33–40 of
the Aβ1−40 peptide
Phase 2
2 phase 1 studies showed
favorable safety proﬁles,
with no microhemorrhage,
ARIA-E, or encephalitis
[67, 68]
BAN2401 Eisai Co., Ltd.
Humanized monoclonal
antibody that selectively
recognizes and eliminates Aβ
protoﬁbrils
Phase I No clinical data have been
p r e s e n t e dt od a t e —
Aβ:betaamyloid;ApoE4:apolipoproteinE4A;DAS-Cog:Alzheimer’sDiseaseAssessmentScale-CognitiveSubscale;DAD:DisabilityAssessmentforDementia;
Ig: immunoglobulin.
In addition, a phase 2 study evaluating biomarkers with
solanezumab in individuals with or without AD is currently
in the recruitment phase (NCT01148498).
5.2.2. Ponezumab. Ponezumab (PF-04360365) is a human-
ized IgG2deltaA monoclonal antibody that binds to amino
acids 33–40 of the beta-amyloid1−40 peptide [67]. Two 1-
year, phase 1 studies were performed to assess the safety,
pharmacokinetics, and pharmacodynamics of ponezumab
in patients with mild-to-moderate AD [67–69]. In the ﬁrst
study, which was randomized and double-blinded, patients
received placebo or ponezumab 0.1, 0.3, 1, 3, or 10mg/kg
via 2-hour infusion; in the second study, an open-label,
parallel-group study, patients received ponezumab 1, 3, 5, or
10mg/kg via 10-minute infusion [69]. All AEs were mild or
moderate, with no serious AEs considered to be related to
studydrug[67,68].Inthe2-hour infusionstudy, onepatient
receiving ponezumab 10mg/kg had a mild hypersensitivity
reaction, and a preexisting brain lesion showed a slight
increase in size in a patient receiving ponezumab 0.1mg/kg
[68].Nonewmicrohemorrhage,ARIA-E,orencephalitiswas
found in either study [67, 68]. Ponezumab showed linear
pharmacokinetics in both studies [67–70]. Low ponezumab
concentrations were detected in CSF in 2 out of 8 patients
receiving the highest dose (10mg/kg) in the 2-hour infusion
study, but ponezumab was not detected in the CSF in the
10-minute infusion study [67–69]. No antidrug antibodies
were detected in either study [69]. In the 2-hour infusion
study, there were dose-dependent increases in CSF beta
amyloid1−x and increases from baseline to day 29 in CSF beta
amyloid1−x and CSF beta-amyloid1−42 with the 10mg/kg
dose [68, 69]. Mass spectrometry following immunoprecipi-
tationidentiﬁedelevatedlevelsofbeta-amyloid1−40 andbeta-
amyloid11−40 in CSF following a single dose of 10mg/kg
ponezumab in patients with mild-to-moderate AD [71].
In Japanese patients with mild-to-moderate AD, single-
dose ponezumab (0.1–10mg/kg) showed similar safety and
pharmacokinetic proﬁles as in Western patients [72, 73].
Studies of multiple-dose ponezumab in patients with mild-
to-moderate AD are currently in progress (NCT00722046;
NCT01125631), and a phase 1 study investigating the eﬀects
on single-dose ponezumab on beta amyloid in AD patientsInternational Journal of Alzheimer’s Disease 11
and in healthy volunteers is currently recruiting patients
(NCT01005862).
5.2.3. Gantenerumab. Gantenerumab (RO4909832/R1450/
RG1450), another monoclonal antibody that targets beta
amyloid, is currently in clinical development. A phase 1,
multiple ascending dose study of gantenerumab in patients
with AD has been completed (NCT00531804), while a phase
2studyinpatientswithprodromalADiscurrentlyrecruiting
patients (NCT01224106).
5.2.4. BAN2401. BAN2401 is a humanized monoclonal
antibody that targets beta-amyloid protoﬁbrils [74]. A phase
1 single- and multiple-ascending dose study of BAN2401 in
patients with mild-to-moderate AD is currently recruiting
patients (NCT01230853).
5.2.5. Intravenous Immunoglobulin. Putative clinical eﬃcacy
data for intravenous immunoglobulin (IVIG) have been
reported in 2 small open-label studies. Dodel et al. adminis-
tered monthly IVIG to 5 AD patients over a 6-month period
anddemonstratedadecreaseintotalCSFbeta-amyloidlevels
and an increase in total beta-amyloid serum levels, with
no change in beta amyloid1−42 in either compartment [75].
The authors reported a slight improvement in mean ADAS-
cog and MMSE scores [75]. The second study involved the
administration of IVIG to 8 patients with mild AD and
demonstrated a dose-proportional increase in serum anti-
beta-amyloid antibodies and a decrease in CSF beta amyloid
[76].TheCSFbeta-amyloidchangesweretransient,reverting
to baseline levels after the discontinuation of IVIG infusions
and decreasing again when infusions were restarted [76].
Mean MMSE scores increased during the ﬁrst 6 months of
IVIG, declined when infusions were withheld, and stabilized
when infusions were restarted [76]. There was no placebo
group in either of these 2 studies, sample sizes were very
small, and no brain MRI scans were performed [75, 76].
No serious treatment-emergent AEs were reported [75,
76]. Another study employed a retrospective case-control
analysis to demonstrate that previous treatment with IVIG
was associated with a reduced risk of AD development
[77]. The possible beneﬁts of IVIG, if any, would likely be
attributed to the presence of naturally occurring anti-beta-
amyloid antibodies in human plasma [26]. Two IVIG clinical
trials have been completed (NCT00299988; NCT00812565),
and 2 are currently recruiting patients: one phase 2 study
(NCT01300728) and one phase 3 trial (NCT00818662).
6. Conclusions andFutureDirections
More than 100 years after the initial description of AD and
the identiﬁcation of beta amyloid as a key pathologic com-
ponent, the search for eﬀective anti-beta-amyloid therapies
continues, and immunotherapeutic approaches are poised
at the front lines of the anti-beta-amyloid battle. Although
the preclinical literature is resplendent with examples of
eﬀective beta-amyloid clearance, initial attempts to translate
theseearlysuccessesintosafeandeﬀectiveADtherapieswere
marred by the development of serious and severe side eﬀects
in some patients. The next generation of immunotherapies,
both active and passive, must demonstrate an acceptable
safety proﬁle and the ability to clear beta amyloid, ultimately
slowing or halting clinical disease progression. As several
pivotal clinical trials in patients with mild-to-moderate AD
near completion, studies in patients with mild cognitive
impairment/prodromalADarejustbeginning,withthehope
that targeting beta amyloid earlier in the disease process will
provide better clinical outcomes.
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